Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | SFRP1 | Q8N474 | 4/20 | 0.32 |
| ▸ | WNT3 | P56703 | 2/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477204 | 0.92 | TACR1 (0.41) | EPHX2TACR1 | |
| SCHEMBL2473244 | 0.92 | TACR1 (0.41) | EPHX2TACR1 | |
| SCHEMBL12200760 | 0.91 | EPHX2 (0.38) | EPHX2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL2479916 | 0.89 | TACR1 (0.38) | EPHX2TACR1BRD3ALDH1A1 | |
| SCHEMBL2479914 | 0.89 | TACR1 (0.38) | EPHX2TACR1BRD3ALDH1A1 | |
| SCHEMBL13232815 | 0.85 | TACR1 (0.43) | TACR1 | |
| SCHEMBL2479211 | 0.82 | TACR1 (0.41) | EPHX2TACR1 | |
| SCHEMBL2976725 | 0.82 | TACR1 (0.41) | EPHX2TACR1 | |
| SCHEMBL2479681 | 0.80 | LMNA (0.36) | EPHX2NPSR1LMNAMEN1KMT2A | |
| SCHEMBL2479682 | 0.80 | LMNA (0.36) | EPHX2NPSR1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |